Homepage > Company > Media > Pharma News > 2018 > Tetraphase's antibiotic fails late-stage study, shares plummet

Tetraphase's antibiotic fails late-stage study, shares plummet

(Reuters) - Tetraphase Pharmaceuticals Inc said on Tuesday its lead experimental antibiotic to treat serious infections did not meet the main goals in a late-stage study, sending its shares plunging more than 60 percent in after-market trading.

The antibiotic, eravacycline, was being studied in a pivotal 1,205 patient study for the treatment of complicated urinary tract infections.

Tetraphase said the drug did not achieve the main goal of non-inferiority compared to patients who were treated with Merck’s drug, ertapenem.

Eravacycline is a synthetic tetracycline derivative for drug-resistant bacterial infections administered intravenously in hospital.

The company in January filed a marketing application for eravacycline with the U.S. Food and Drug Administration to treat intra-abdominal infections.

Tetraphase Chief Executive Guy Macdonald said last year annual sales of the company’s lead drug for serious bacterial infections could climb as high as $700 million, if approved.

The company’s shares were down 58 percent at $2.27.

Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila

FEBRUARY 14, 2018

https://www.reuters.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...